Mild Cognitive Impairment: Current Research and Clinical Implications

ABSTRACT

Mild cognitive impairment refers to the transitional state between the cognitive changes of normal aging and the fully developed clinical features of dementia. This topic has received a great deal of attention in the literature in recent years and is being proposed for clinical applications as well. Clinical guidelines, including the original memory-focused criteria and the more recent broadly defined set of criteria, will be presented. The clinical outcome of individuals with mild cognitive impairment will be discussed and several explanations for variability in the literature will be considered. Predictors of progression, including genetic, neuroimaging, biomarker, and clinical characteristics, will be presented, as will the controversies regarding the underlying neuropathology of mild cognitive impairment. The recently completed mild cognitive impairment clinical trials will be discussed and the lessons learned from them translated into recommendations for future investigations. Finally, the clinical utility of mild cognitive impairment, its incorporation into clinical practice, and directions for future research will be proposed.

Mild cognitive impairment - memory - Alzheimer's disease

REFERENCES

• 1 Walker L C, Ibegbu C C, Todd C W et al.. Emerging prospects for the disease-modifying treatment of Alzheimer's disease.  Biochem Pharmacol. 2005;  69 1001-1008
• 2 Kral V A. Senescent forgetfulness: benign and malignant.  Can Med Assoc J. 1962;  86 257-260
• 3 Crook T, Bartus R T, Ferris S H et al.. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of a National Institute of Mental Health Work Group.  Dev Neuropsychol. 1986;  2 261-276
• 4 Levy R. Aging-associated cognitive decline.  Int Psychogeriatr. 1994;  6 63-68
• 5 LaRue A. Aging and Neuropsychological Assessment. New York; Plenum Press 1992
• 6 Graham J E, Rockwood K, Beattie B L et al.. Prevalence and severity of cognitive impairment with and without dementia in an elderly population.  Lancet. 1997;  349 1793-1796
• 7 Fisk J D, Merry H R, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment.  Neurology. 2003;  61 1179-1184
• 8 Reisberg B, Ferris S H, de Leon M J, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia.  Am J Psychiatry. 1982;  139 1136-1139
• 9 Flicker C, Ferris S H, Reisberg B. A two-year longitudinal study of cognitive function in normal aging and Alzheimer's disease.  J Geriatr Psychiatry Neurol. 1993;  6 84-96
• 10 Kluger A, Ferris S H, Golomb J, Mittelman M S, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly.  J Geriatr Psychiatry Neurol. 1999;  12 168-179
• 11 Kluger A, Gianutsos J G, Golomb J et al.. Patterns of motor impairment in normal aging, mild cognitive decline, and early Alzheimer's disease.  J Gerontol B Psychol Sci Soc Sci. 1997;  52 P28-P39
• 12 Kluger A, Gianutsos J G, Golomb J, Ferris S H, Reisberg B. Motor/psychomotor dysfunction in normal aging, mild cognitive decline, and early Alzheimer's disease: diagnostic and differential diagnostic features.  Int Psychogeriatr. 1997;  9(suppl 1) 307-316 , discussion 317-321
• 13 Petersen R C, Doody R, Kurz A et al.. Current concepts in mild cognitive impairment.  Arch Neurol. 2001;  58 1985-1992
• 14 Petersen R C. Conceptual overview. In: Petersen RC Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York; Oxford University Press 2003: 1-14
• 15 Petersen R C, Smith G E, Waring S C et al.. Mild cognitive impairment: clinical characterization and outcome.  Arch Neurol. 1999;  56 303-308
• 16 Ganguli M, Dodge H H, Shen C, DeKosky S T. Mild cognitive impairment, amnestic type: an epidemiologic study.  Neurology. 2004;  63 115-121
• 17 Gauthier S, Reisberg B, Zaudig M et al.. Mild cognitive impairment.  Lancet. 2006;  367 1262-1270
• 18 Larrieu S, Letenneur L, Orgogozo J M et al.. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort.  Neurology. 2002;  59 1594-1599
• 19 Unverzagt F W, Gao S, Baiyewu O et al.. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging.  Neurology. 2001;  57 1655-1662
• 20 Bennett D A, Wilson R S, Schneider J A et al.. Natural history of mild cognitive impairment in older persons.  Neurology. 2002;  59 198-205
• 21 Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status [see comments].  Lancet. 2000;  355 225-228
• 22 Winblad B, Palmer K, Kivipelto M et al.. Mild cognitive impairment: beyond controversies, towards a consensus.  J Intern Med. 2004;  256 240-246
• 23 Petersen R C. Mild cognitive impairment as a diagnostic entity.  J Intern Med. 2004;  256 183-194
• 24 Mueller S G, Weiner M W, Thal L J et al.. The Alzheimer's disease neuroimaging initiative. In: Pettrella JR, Doraiswamy PM Neuroimaging Clinics of North America: Alzheimer's Disease-100 Years of Progress. Philadelphia; Elsevier Saunders 2005: 869-877
• 25 Petersen R C. Clinical evaluation. In: Petersen RC Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York; Oxford University Press 2003: 229-242
• 26 Daly E, Zaitchik D, Copeland M et al.. Predicting conversion to Alzheimer disease using standardized clinical information.  Arch Neurol. 2000;  57 675-680
• 27 Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study.  Neurology. 2001;  56 37-42
• 28 Aggarwal N T, Wilson R S, Bienias J L, Berry-Kravis E, Bennett D A. The Apolipoprotein E4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.  Neurocase. 2005;  11 3-7
• 29 Petersen R C, Waring S C, Smith G E, Tangalos E G, Thibodeau S N. Predictive value of APOE genotyping in incipient Alzheimer's disease.  Ann NY Acad Sci. 1996;  802 58-69
• 30 Petersen R C, Smith G E, Ivnik R J et al.. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.  JAMA. 1995;  273 1274-1278
• 31 Petersen R C, Thomas R G, Grundman M et al.. Donepezil and vitamin E in the treatment of mild cognitive impairment.  N Engl J Med. 2005;  352 2379-2388
• 32 Dubois B, Albert M L. Amnestic MCI or prodromal Alzheimer's disease?.  Lancet Neurol. 2004;  3 246-248
• 33 Fox N C, Crum W R, Scahill R I et al.. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images.  Lancet. 2001;  358 201-205
• 34 Jack Jr C R. Magnetic resonance imaging. In: Petersen RC Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York; Oxford University Press 2003: 105-132
• 35 Killiany R J, Gomez-Isla T, Moss M et al.. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.  Ann Neurol. 2000;  47 430-439
• 36 Jack Jr C R, Petersen R C, Xu Y C et al.. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.  Neurology. 1999;  52 1397-1403
• 37 Jack Jr C R, Petersen R C, Xu Y et al.. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.  Neurology. 2000;  55 484-489
• 38 Jack Jr C R, Shiung M M, Weigand S D et al.. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.  Neurology. 2005;  65 1227-1231
• 39 Reiman E M, Caselli R J, Yun L S et al.. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E.  N Engl J Med. 1996;  334 752-758
• 40 Small G W, Mazziotta J C, Collins M T et al.. Apolipoprotein E Type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.  JAMA. 1995;  273 942-947
• 41 Drzezga A, Grimmer T, Riemenschneider M et al.. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.  J Nucl Med. 2005;  46 1625-1632
• 42 Klunk W E, Engler H, Nordberg A et al.. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.  Ann Neurol. 2004;  55 306-319
• 43 Small W, Kepe V, Ercoli L M et al.. FDDNP-PET binding differentiates MCI from dementia and increases with clinical progression.  Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2006;  2(suppl 1) S318-S319
• 44 Hansson O, Zetterberg H, Buchhave P et al.. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.  Lancet Neurol. 2006;  5 228-234
• 45 Markesbery W R, Schmitt F A, Kryscio R J et al.. Neuropathologic substrate of mild cognitive impairment.  Arch Neurol. 2006;  63 38-46
• 46 DeKosky S T, Ikonomovic M, Styren S et al.. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortes of elderly subjects with mild cognitive impairment.  Ann Neurol. 2002;  51 145-155
• 47 Bennett D A, Schneider J A, Bienias J L, Evans D A, Wilson R S. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.  Neurology. 2005;  64 834-841
• 48 Petersen R C, Parisi J E, Dickson D W et al.. Neuropathology of amnestic mild cognitive impairment.  Arch Neurol. 2006;  63 665-672
• 49 Jicha G A, Parisi J E, Dickson D W et al.. Neuropathological outcome of mild cognitive impairment following progression to clinical dementia.  Arch Neurol. 2006;  63 674-681
• 50 Geda Y E, Petersen R C. Clinical trials in mild cognitive impairment. In: Gauthier S, Cummings JL Alzheimer's Disease and Related Disorders Annual 2001. London; Martin Dunitz 2001: 69-83
• 51 Petersen R C. Mild cognitive impairment clinical trials.  Nat Rev Drug Discov. 2003;  2 646-653
• 52 Gauthier S. Pharmacotherapy of mild cognitive impairment.  Dialogues Clin Neurosci. 2004;  6 391-395
• 53 Gold M, Francke S, Nye J S et al.. Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment.  Neurobiol Aging. 2004;  25 S521
• 54 Feldman H, Scheltens P, Scarpini E et al.. Behavioral symptoms in mild cognitive impairment.  Neurology. 2004;  62 1199-1201
• 55 Thal L J, Ferris S H, Kirby L et al.. A randomized, double-blind study of rofecoxib in patients with mild cognitive impairment.  Neuropsychopharmacology. 2005;  30 1204-1215
• 56 Lines C R, McCarroll K A, Lipton R B, Block G A. Telephone screening for amnestic mild cognitive impairment.  Neurology. 2003;  60 261-266
• 57 Cooper J K, Mungas D, Verma M, Weiler P G. Psychotic symptoms in Alzheimer's disease.  Int J Geriatr Psychiatry. 1991;  6 721-726
• 58 Petersen R C, O'Brien J. Mild cognitive impairment should be considered for DSM-V.  J Geriatr Psychiatry Neurol. 2006;  19 147-154